The transplant programs at NewYork-Presbyterian rank among the best in the nation for volume and survival. Specialists from Columbia and Weill Cornell Medicine lead the field in medical and surgical management of transplant patients, expanding access to lifesaving procedures and improving patient outcomes. In 2025, teams across the institution achieved remarkable milestones, including performing New York’s first heart-lung-liver and fully robotic liver transplant surgeries; developing noninvasive methods to monitor graft rejection in pediatric patients; and successfully treating multiple pediatric and adult patients through innovative domino procedures. These achievements reflect our steadfast commitment to advancing treatment for all patients.
The transplant program at NewYork-Presbyterian, Columbia, and Weill Cornell Medicine is among the longest established and most experienced program in the country. Due to their experience and expertise, our physicians can confidently care for some of the most complex transplants, including multi-organ transplants. Patients come to us from across the country and around the world for better outcomes and innovative procedures that allow for quicker access to transplants and also quicker recovery.
Transplant
Featured Updates
On this episode of Advances in Care, Erin Welsh is joined by Dr. Lawrence Lustig, chair of the Department of Otolaryngology – Head & Neck Surgery at NewYork-Presbyterian and Columbia. Dr. Lustig has spent decades working to advance various interventions to treat genetic hearing loss and after years of research his team was the first to show that gene therapies could be effective at reversing genetic hearing loss in mouse models and eventually, humans. In April 2026, the FDA approved the first ever gene therapy for genetic deafness based on the work pushed forward by Dr. Lustig.










